Printer Friendly

FDA ADVISORY COMMITTEE ENDORSES MYOSCINT WOULD BE FIRST MAB-BASED IMAGING AGENT IN THE UNITED STATES

 FDA ADVISORY COMMITTEE ENDORSES MYOSCINT
 WOULD BE FIRST MAB-BASED IMAGING AGENT IN THE UNITED STATES
 BETHESDA, Md., Nov. 26 /PRNewswire/ -- The Food and Drug Administration's Biological Response Modifiers Advisory Committee today unanimously recommended that Myoscint(R) (imciromab pentetate) be cleared for marketing for the detection of the presence, location, and extent of myocardial necrosis in the setting of acute ischemic heart disease.
 Myoscint is a radiolabeled imaging agent that uses a monoclonal antibody fragment to seek out and bind to dead heart tissue.
 Myoscint is the first monoclonal antibody-based imaging agent to receive such a recommendation in the United States. The FDA will now consider the committee's advice.
 "This decision by the committee reinforces the potential contribution of monoclonal antibodies to human health care," said James E. Wavle, Jr., Centocor's president and chief executive officer. "We are looking forward to working with the FDA on the final approval of Myoscint so that it can be available as another tool to help U.S. physicians to diagnose heart attacks and better discern the degree of injury to the heart."
 Myocardial necrosis, or heart-tissue death, typically occurs during a heart attack. About 1.5 million people in the United States suffer heart attacks every year; about 1 million survive, many of whom can benefit from continuing medical care.
 Myoscint is a murine monoclonal antibody Fab fragment bound to DTPA (diethylenetriaminepentaacetic acid) that is radiolabeled with indium-111 for cardiac imaging performed with a nuclear medicine gamma camera employing either planar or tomographic techniques. Myoscint binds with high affinity and specificity to myosin, a protein exposed in necrotic myocardial cells. Trials of Myoscint involving more than 1,000 patients have been conducted in the United States, Canada, and Europe.
 Myoscint is currently available in several European nations, where Centocor markets it directly. McNeil Pharmaceutical, an affiliate of Johnson & Johnson, will market Myoscint in the United States.
 Centocor, Inc. (NASDAQ: CNTO), based in Malvern, Pa., develops, manufactures and markets diagnostic and therapeutic products for human health care. The company's products are based on monoclonal antibody technology and are primarily intended for use in infectious, cardiovascular, and autoimmune diseases and cancer.
 /delval/
 -0- 11/26/91
 /CONTACT: Charles C. Cabot III, 215-889-4456, Richard M. Koenig, 215-651-6122, or Thomas A. Pearson, 215-648-3975, all of Centocor/
 (CNTO) CO: Centocor, Inc. ST: Pennsylvania IN: MTC SU:


MK -- PH036 -- 7380 11/26/91 14:16 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 26, 1991
Words:396
Previous Article:FANNIE MAE SELECTS THREE RECIPIENTS FOR SPRING 1992 UNIVERSITY LECTURES ON INTERNATIONAL HOUSING AND FINANCE
Next Article:METALCLAD CORP. REPORTS RESULTS
Topics:


Related Articles
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER
CYTOGEN AND CETUS ANNOUNCE SPAIN APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
CYTOGEN AND CHIRON ANNOUNCE ITALY APPROVES ONCOSCINT(R) CR103 CANCER IMAGING AGENT
NEORX RECEIVES FAVORABLE FDA REVIEW LETTER
HUMAN CLINICAL TRIALS OF VIAGENE'S GENE TRANSFER THERAPEUTIC FOR AIDS CLEARED BY FDA ADVISORY COMMITTEE
FDA APPROVES ONCOSCINT AND INDICLOR FOR COLORECTAL AND OVARIAN CANCER DETECTION; FIRST CANCER IMAGING AGENT BASED ON A MONOCLONAL ANTIBODY
CENTOCOR REPORTS FOURTH QUARTER AND FULL-YEAR 1995 FINANCIAL RESULTS
FDA Resumes Review of SONUS' EchoGen(R) Emulsion
FDA Advisory Committee Endorses Proposed Labeling for Genetics Institute's ReFacto(R) Antihemophilic Factor (Recombinant), A Treatment For Hemophilia...
Genzyme General Says Fabrazyme(TM) BLA Will Not Need December Advisory Committee Review.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters